Elahere ® (Mirvetuximab Soravtansine-Gynx) shows the constant benefit of survival in long-term analysis for certain patients with ovarian cancer

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.